Stuart A. Green

Efficacy of tildrakizumab for moderate‐to‐severe plaque psoriasis: pooled analysis of three randomized controlled trials at weeks 12 and 28

S. Green, M. Gooderham, K. Papp, 2019, Journal of the European Academy of Dermatology and Venereology : JEADV.

Safety of tildrakizumab for moderate‐to‐severe plaque psoriasis: pooled analysis of three randomized controlled trials

A. Kimball, S. Green, M. Gooderham, 2018, The British journal of dermatology.